The audit committee for Bruker Corp. (NYSE:BRKR) will have to do without the services of Collin D’Silva, who stepped down from the panel March 9 but remains a member of Bruker’s board of directors.
The Billerica, Mass.-based scientific instruments maker has 180 days from D’Silva’s resignation, or until Sept. 7, to find someone to replace him on the audit committee or it will risk de-listing from the NASDAQ stock exchange, according to a regulatory filing.
NASDAQ rules require audit committees to consist of three members; with D’Silva stepping down Bruker has only two directors on the committee. Last week the exchange informed the company, which said it plans to fill the seat as soon as possible, that it is out of compliance and must fill the seat before the end of the so-called "cure period."
D’Silva joined Bruker’s board of directors in February 2000, according to the company’s website. His resumé includes stints as chairman of Transgenomic Inc. and president and CEO of CETAC Technologies Inc.